Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00588536
Other study ID # 94-132
Secondary ID
Status Completed
Phase Phase 2
First received December 26, 2007
Last updated April 16, 2015
Start date January 1995
Est. completion date June 2009

Study information

Verified date April 2015
Source Memorial Sloan Kettering Cancer Center
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The objective of this study is to determine the incidence of complete and partial response and the duration of response in patients with Langerhans Cell Histiocytosis (LCH) treated with sequential administration of oral 6-Thioguanine (6-TG) after Methotrexate (MTX).


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date June 2009
Est. primary completion date July 2008
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients with histologic proof of LCH who have multifocal or multisystem disease involvement.

- Patients must have a life expectancy of at least 8 weeks.

- All patients must have ECOG performance level rating of-< 2.

- Patients or their parents (guardian) must sign an informed consent indicating that they are aware of the investigational nature of the study, using commercially available drugs.

- Patients must have recovered from the toxic effects of prior therapy before entering this study or at least 2 weeks should have elapsed since the end of last course of chemotherapy.

- Patients must have adequate liver function (bilirubin _< 2.0 mg/dl, SGOT less than 1.5 times normal (unless it is due to disease), adequate renal function (creatinine <_ 1.5 mg/dl, creatinine clearance >_ 60 ml/min/1.73 m2) and normal electrolytes.

- Patients should have a granulocyte count > 500/uL and a platelet count >_ 100,000/uL (unless due to disease involvement of the bone marrow).

- Male and female patients of child-bearing age should use effective methods of contraception, if sexually active.

Exclusion Criteria:

- Patients with active infections or significant medical conditions other than their disease (LCH) shall be excluded.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Methotrexate
MTX 30mg/m2 (or 1mg/kg for infants) orally, given in three equally divided doses at 0,8, and 16hrs
6-Thioguanine
6-TG 300mg/m2 (or 10mg/kg for infants) orally, given in one dose.
Leucovorin Calcium
5mg orally at 36,48, and 60hrs (or 12 hrs after the dose of 6-TG and then every 12 hrs for a total of 3 doses)

Locations

Country Name City State
United States Memorial Sloan-Kettering Cancer Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the Incidence of Complete and Partial Response and the Duration of Response in Patients With Langerhans Cell Histiocytosis (LCH) Treated With Sequential Administration of Oral 6-TG After MTX. Conclusion of the study No
See also
  Status Clinical Trial Phase
Completed NCT03270020 - Denosumab for the Treatment of Adult LCH Phase 2
Recruiting NCT05997602 - To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH Phase 2
Recruiting NCT05915208 - Histiocytic Disorder Follow-up Study
Completed NCT03096782 - Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Phase 2
Recruiting NCT04120519 - Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis Phase 2
Not yet recruiting NCT05477446 - Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With R/R Langerhans Cell Histiocytosis Phase 1
Recruiting NCT04121819 - AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis Phase 2
Recruiting NCT05284942 - Central China Rosai-Dorfman Disease Registry Phase 4
Active, not recruiting NCT03220035 - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT02608619 - Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement
Completed NCT01395004 - A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis Phase 2
Recruiting NCT02205762 - LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis Phase 2/Phase 3
Active, not recruiting NCT02425904 - Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders Phase 2
Recruiting NCT02670707 - Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH) Phase 3
Completed NCT02665546 - Evaluation of Exercise Capacity and Exercise Limitation in Patients With Pulmonary Langerhans Cell Histiocytosis
Recruiting NCT04627090 - LCH in Adults: a Collaborative, Prospective-retrospective, Observational Study
Recruiting NCT03585686 - A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation Phase 2
Recruiting NCT03155620 - Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Phase 2
Recruiting NCT04773366 - A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol Phase 3
Completed NCT02389400 - Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis Phase 2